239 results on '"Baseggio L"'
Search Results
102. Lymphoma diagnosis: lessons learned from the comparison of histology and cytology associated with flow cytometry.
- Author
-
Aussedat G, Fontaine J, Gerland LM, Traverse-Glehen A, and Baseggio L
- Subjects
- Biopsy, Fine-Needle, Cytodiagnosis, Flow Cytometry, Humans, Retrospective Studies, Lymphoma diagnosis
- Abstract
For lymphoma diagnosis, the flow cytometry (FCM) and cytology associated with FCM (C-FCM) performed on fine needle aspiration (FNA) or cell suspension/imprints from fresh tissue display a good concordance (from 85 to 90%) with the diagnosis made using histological data. Herein is reported a retrospective series of discordant cases, five of them are discussed in details, and some recommendations are proposed for the interpretation of C-FCM data. Firstly, this review highlights the importance of analyzing simultaneously the cytological and FCM data. In particular, the cytological data are crucial to interpret FCM data and/or to complete Ab panels when the strategy of the laboratory is to systematically perform a first screening, which don't always allow the detection of lymphoma cells. Secondly, this report underlines that cytology and FCM analysis should be followed by a confrontation/discussion with a pathologist. Finally, C-FCM appears to be a rapid and particularly important technic to guide the choice of the following diagnosis tools (IHC and genetic).
- Published
- 2022
- Full Text
- View/download PDF
103. [Atlas of flow cytometry images: Lymphoproliferative syndromes].
- Author
-
Mayeur-Rousse C, Bouyer S, and Baseggio L
- Subjects
- Flow Cytometry, Humans, Immunophenotyping, Syndrome, Lymphoproliferative Disorders diagnosis
- Published
- 2021
- Full Text
- View/download PDF
104. Age-Related Differences in Hamstring Flexibility in Prepubertal Soccer Players: An Exploratory Cross-Sectional Study.
- Author
-
Abate Daga F, Panzolini M, Allois R, Baseggio L, and Agostino S
- Abstract
This study aimed to investigate the hamstring flexibility rate among prepubertal soccer players from U8 to U12 and the role of age and soccer years of practice on the course of hamstring flexibility. Six hundred eleven young Italian soccer players from a local soccer school in Turin were recruited for this research and assigned to each group according to their chronological age (U8 = 124 players; U9 = 130 players; U10 = 151 players; U11 = 89 players; and U12 = 120 players). Hamstring flexibility was measured using the Sit and Reach Test (SAR), while data analysis was run using a one-way analysis of variance (one-way ANOVA). Furthermore, Tuckey's post hoc was used to determine differences among the classes of age. Finally, a bivariate ordinal regression analysis was used to evaluate a potential association between age categories and hamstrings flexibility. In addition, multivariable ordinal regression was used to analyze this relationship adjusted for the Body Mass Index (BMI). The one-way ANOVA showed significant differences in flexibility among groups ( F = 32.76, P < 0.0001). Tuckey's post hoc identified significant differences between U8 and U10 ( p < 0.01; -2,39 cm of hamstring stretching), U8 and U11 ( p < 0.05; -2.19 cm), U8 and U12 ( p < 0.0001; -5.90), U9 and U12 ( p < 0.0001; -4.98 cm), U10 and U12 ( p < 0.0001; -3.5 cm), U11 and U12 ( p < 0,001; -3.70 cm). In the bivariate ordinal regression analysis, there was a negative association between the age categories and hamstrings flexibility ( R
2 = 0.137; p < 0.0001). The association persisted in multivariable ordinal regression analysis adjusted for BMI ( R2 = 0.138; p < 0.0001). This study underlines changes in hamstring flexibility across different age groups of prepubertal soccer players. The older and more experienced in soccer are less flexible than the younger, considering the hamstring muscles. Thus, appropriate stretching protocols should be included in prepubertal soccer training to avoid the risk of lead players to excess hamstring tightness., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Abate Daga, Panzolini, Allois, Baseggio and Agostino.)- Published
- 2021
- Full Text
- View/download PDF
105. The structural parameters and flags of the Sysmex XN™ analyser: Are they discriminative between reactive and malignant lymphocytosis in the context of lymphocyte counts above 5 × 10 9 /L in adults?
- Author
-
Cornet E, Comte E, and Baseggio L
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Hematologic Neoplasms diagnosis, Hematologic Neoplasms pathology, Humans, Lymphocytosis diagnosis, Male, Middle Aged, Young Adult, Lymphocyte Count methods, Lymphocytes pathology, Lymphocytosis pathology
- Published
- 2021
- Full Text
- View/download PDF
106. New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas.
- Author
-
Donzel M, Baseggio L, Fontaine J, Pesce F, Ghesquières H, Bachy E, Verney A, and Traverse-Glehen A
- Subjects
- Biology, Humans, Splenectomy, Tumor Microenvironment, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Splenic Neoplasms diagnosis, Splenic Neoplasms genetics, Splenic Neoplasms therapy
- Abstract
Splenic marginal zone lymphoma (SMZL) is a small B-cell lymphoma, which has been recognized as a distinct pathological entity since the WHO 2008 classification. It classically presents an indolent evolution, but a third of patients progress rapidly and require aggressive treatments, such as immuno-chemotherapy or splenectomy, with all associated side effects. In recent years, advances in the comprehension of SMZL physiopathology have multiplied, thanks to the arrival of new devices in the panel of available molecular biology techniques, allowing the discovery of new molecular findings. In the era of targeted therapies, an update of current knowledge is needed to guide future researches, such as those on epigenetic modifications or the microenvironment of these lymphomas.
- Published
- 2021
- Full Text
- View/download PDF
107. Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma.
- Author
-
Debliquis A, Baseggio L, Bouyer S, Guy J, Garnache-Ottou F, Genevieve F, Mayeur-Rousse C, Letestu R, Chapuis N, Harrivel V, Bennani H, Lachot S, Loosveld M, Nicolino-Brunet C, Pérès M, Roussel M, Veyrat-Masson R, Jacob MC, and Drenou B
- Subjects
- Adult, Female, Gene Expression Regulation, Neoplastic genetics, Humans, Immunoconjugates genetics, Immunoconjugates immunology, Immunohistochemistry, Lymphoma, Non-Hodgkin genetics, Lymphoma, Non-Hodgkin pathology, Male, Middle Aged, Tumor Microenvironment immunology, Flow Cytometry standards, Ki-1 Antigen genetics, Lymphoma, Non-Hodgkin diagnosis, Tumor Microenvironment genetics
- Abstract
CD30 transmembrane receptor, a member of the tumor necrosis factor receptor family, is expressed in different lymphomas. Brentuximab vedotin (BV), a CD30 monoclonal antibody (Ab)-drug conjugate, is effective in CD30-positive lymphomas. However, the response to BV is not always correlated to CD30 expression detected by immunohistochemistry (IHC). The objectives of this study were to standardize and evaluate CD30 intensity by flow cytometry (FCM) in non-Hodgkin's lymphomas. Twelve centers analyzed 161 cases on standardized cytometers using normalized median fluorescence intensity (nMFI30) of three different Abs, of which one clone can recognize the same epitope as BV. FCM distinguished four groups of cases: negative group (n = 110) which showed no expression with the three clones; high positive group (n = 13) which gave nMFI30 > 5% with all tested clones; dim positive group (n = 17) which showed nMFI30 > 1% with all tested clones and <5% for at least one; discordant group (n = 21) with positive and negative expression of the different clones. In consistency with the literature, CD30 was positive in all anaplastic large cell lymphomas, in some diffuse large B-cell lymphomas (DLBCL), and in other rare lymphomas. FCM results were concordant with those of IHC in 77% of cases. Discrepancies could be explained by clones-related differences, microenvironment, or intracytoplasmic staining. Interestingly, FCM was more sensitive than IHC in 11% of cases, especially in DLBCL. Multicenter standardized FCM of specific CD30 could improve case detection and extend the treatment of BV to various CD30-positive lymphomas., (© 2020 International Clinical Cytometry Society.)
- Published
- 2021
- Full Text
- View/download PDF
108. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
- Author
-
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, and Cymbalista F
- Subjects
- Aged, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Cyclophosphamide administration & dosage, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Male, Prognosis, Retrospective Studies, Rituximab administration & dosage, Survival Rate, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow pathology, Immunotherapy mortality, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Neoplasm, Residual pathology
- Abstract
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10
-5 ) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD < 0.01% to MRD ≥ 0.01% increased the proportion of cases with positive MRD in blood by 39% and in bone marrow by 27%. Compared to low-level positive MRD < 0.01%, undetectable MRD was associated with significantly longer progression-free survival (PFS) when using blood (72.2 versus 42.7 months; hazard ratio 0.40, p = 0.0003), but not when using bone marrow. Upon further stratification, positive blood MRD at any level, compared to undetectable blood MRD, was associated with shorter PFS irrespective of clinical complete or partial remission, and a lower 5-year PFS rate irrespective of IGHV-mutated or -unmutated status (all p < 0.05). In conclusion, high-sensitivity (0.0007%) MRD assessment in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). Our approach provides a model for future determination of the optimal MRD investigative strategy for any regimen.- Published
- 2021
- Full Text
- View/download PDF
109. Auer-rod like inclusions associated to azurophilic granules in plasma cells neoplasm.
- Author
-
Morin J and Baseggio L
- Subjects
- Humans, Inclusion Bodies, Multiple Myeloma, Plasma Cells
- Published
- 2021
- Full Text
- View/download PDF
110. Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network.
- Author
-
Bommier C, Mauduit C, Fontaine J, Bourbon E, Sujobert P, Huet S, Baseggio L, Hayette S, Laurent C, Bachy E, Ghesquières H, Thieblemont C, Salles G, and Traverse-Glehen A
- Subjects
- Aged, Female, France, Humans, Male, Middle Aged, Retrospective Studies, High-Throughput Nucleotide Sequencing, Lymphoma diagnosis, Lymphoma genetics, Registries
- Abstract
As the impact of targeted next-generation sequencing (TNGS) on daily diagnosis has not been evaluated, we performed TNGS (46 genes) on lymphomas of unclear subtype following expert haematopathological review. The potential impact on patient care and modifications of final diagnosis were divided into major and minor changes according to the European Society of Medical Oncology (ESMO) guidelines. Among 229 patients [19 primary central nervous system lymphomas (PCNSL), 48 large B-cell lymphomas (LBCLs), 89 small BCLs (SBCLs), seven Hodgkin lymphomas (HL), 66 T-cell lymphomas], the overall concordance rate of histological and TNGS diagnosis was 89·5%. TNGS confirmed the histological diagnosis in 144 cases (62·9%), changed the diagnosis in 24 cases (10·5%) and did not help to clarify diagnosis in 61 cases (26·7%). Modifications to the final diagnosis had a clinical impact on patient care in 8·3% of cases. Diagnostic modifications occurred in all types of lymphoma except in PCNSL and HL; the modification rate was 14·6% in SBCL and 12·5% in LBCL. While comparing informative and uninformative cases, no differences were found in terms of DNA amplification, quality or depth of sequencing and biopsy type. The present study highlights that TNGS may directly contribute to a more accurate diagnosis in difficult-to-diagnose lymphomas, thus improving the clinical management in routine practice., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
111. Complete, closed and curated genome sequences of Photobacterium damselae subsp. piscicida isolates from Australia indicate mobilome-driven localized evolution and novel pathogenicity determinants.
- Author
-
Baseggio L, Rudenko O, Buller N, Landos M, Englestädter J, and Barnes AC
- Subjects
- Bacterial Proteins metabolism, Chromosome Mapping, Evolution, Molecular, Photobacterium classification, Photobacterium isolation & purification, Phylogeny, Virulence Factors metabolism, Bacterial Proteins genetics, DNA Transposable Elements, Genome, Bacterial, Photobacterium genetics, Virulence Factors genetics
- Abstract
Despite the recent advances in sequencing technologies, the complete assembly of multi-chromosome genomes of the Vibrionaceae , often containing several plasmids, remains challenging. Using a combination of Oxford Nanopore MinION long reads and short Illumina reads, we fully sequenced, closed and curated the genomes of two strains of a primary aquatic pathogen Photobacterium damselae subsp. piscicida isolated in Australia. These are also the first genome sequences of P. damselae subsp. piscicida isolated in Oceania and, to our knowledge, in the Southern hemisphere. We also investigated the phylogenetic relationships between Australian and overseas isolates, revealing that Australian P. damselae subsp. piscicida are more closely related to the Asian and American strains rather than to the European ones. We investigated the mobilome and present new evidence showing that a host specialization process and progressive adaptive evolution to fish are ongoing in P. damselae subsp. piscicida , and are largely mediated by transposable elements, predominantly in chromosome 2, and by plasmids. Finally, we identified two novel potential virulence determinants in P. damselae subsp. piscicida - a chorismate mutase gene, which is ubiquitously retained and co-localized with the AIP56 apoptogenic toxin-encoding gene on the pPHDP10 plasmid, and transfer-messenger RNA gene ssrA located on the main chromosome, homologous to a critical-to-virulence determinant in Yersinia pseudotuberculosis . Our study describes, to our knowledge, the only fully closed and manually curated genomes of P. damselae subsp. piscicida available to date, offering new insights into this important fish pathogen and its evolution.
- Published
- 2021
- Full Text
- View/download PDF
112. Crystal-storing histiocytosis in Bing-Neel syndrome.
- Author
-
Dumas C and Baseggio L
- Subjects
- Aged, Bendamustine Hydrochloride therapeutic use, Histiocytes ultrastructure, Histiocytosis metabolism, Histiocytosis pathology, Humans, Inclusion Bodies chemistry, Leukoencephalopathies metabolism, Leukoencephalopathies pathology, Male, Plasma Cells ultrastructure, Syndrome, Waldenstrom Macroglobulinemia diagnosis, Waldenstrom Macroglobulinemia drug therapy, Waldenstrom Macroglobulinemia pathology, Bone Marrow ultrastructure, Histiocytosis etiology, Immunoglobulins analysis, Inclusion Bodies ultrastructure, Leukoencephalopathies etiology, Lymph Nodes ultrastructure, Waldenstrom Macroglobulinemia complications
- Published
- 2021
- Full Text
- View/download PDF
113. Game-based versus multilateral approach: effects of a 12-week program on motor skill acquisition and physical fitness development in soccer school children.
- Author
-
Abate Daga F, Baseggio L, Gollin M, and Beratto L
- Subjects
- Child, Exercise Test methods, Humans, Male, Running physiology, Motor Skills physiology, Physical Fitness physiology, Soccer physiology
- Abstract
Background: The purpose of this study was to investigate the effects of a 12-week-game-based training versus a traditional multilateral approach on motor skills acquisition and physical fitness, in a group of U9 children playing soccer., Methods: Forty children aged 9 or younger (U9) recruited from a local soccer school were assigned in a 1:1 ratio to a game-based training program (GB) or a multilateral training (MA) approach. The training programs lasted 12 weeks, and players were tested at baseline and at the end of the program (12-week follow-up). The outcomes were: standing long jump test, shuttle dribble test, 10×5 shuttle run test and Mini-Cooper test., Results: Within-group comparisons showed statistically-significant improvements in both of the groups: standing long lump (P<0.0001), shuttle dribble test (P<0.0001), shuttle run test (P<0.0001) and Mini-Cooper test (P<0.0001). Furthermore, the MA group showed better performance in the shuttle run test after 12 weeks of training compared to the GB group (P=0.0002; +8%)., Conclusions: A multilateral approach promotes physical development in U9 soccer players without affecting learning of-soccer skills. Therefore, a multilateral approach should be included in soccer training programs to ensure an optimal development in young soccer players.
- Published
- 2020
- Full Text
- View/download PDF
114. Lymphoid involvement of cerebrospinal fluid in Lyme disease.
- Author
-
Lefeuve F and Baseggio L
- Subjects
- Back Pain diagnosis, Back Pain etiology, Cerebrospinal Fluid chemistry, Cerebrospinal Fluid immunology, Diagnosis, Differential, Enzyme-Linked Immunosorbent Assay, Humans, Lyme Disease cerebrospinal fluid, Lyme Disease complications, Lyme Disease diagnosis, Lyme Neuroborreliosis cerebrospinal fluid, Lymphocytes pathology, Male, Middle Aged, Paresis diagnosis, Paresis etiology, Plasma Cells cytology, Plasma Cells pathology, Back Pain cerebrospinal fluid, Cerebrospinal Fluid cytology, Lyme Neuroborreliosis diagnosis, Lymphocytes cytology, Paresis cerebrospinal fluid
- Published
- 2020
- Full Text
- View/download PDF
115. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
- Author
-
Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, and Deconinck E
- Subjects
- Acute Disease, Biomarkers, Blood Cell Count, Bone Marrow pathology, Chromosome Aberrations, Clonal Evolution genetics, Dendritic Cells metabolism, Disease Management, Hematopoietic Stem Cell Transplantation, Humans, Immunophenotyping, Leukemia etiology, Leukemia metabolism, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Treatment Outcome, Dendritic Cells pathology, Leukemia diagnosis, Leukemia therapy
- Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a retrospective, observational study of 86 patients (2000-2013), we described clinical and biological data focusing on morphologies and immunophenotype. We found expression of markers associated with plasmacytoid dendritic cell origin (HLA-DRhigh, CD303+, CD304+, and cTCL1+) plus CD4 and CD56 and frequent expression of isolated markers from the myeloid, B-, and T-lymphoid lineages, whereas specific markers (myeloperoxidase, CD14, cCD3, CD19, and cCD22) were not expressed. Fifty-one percent of cytogenetic abnormalities impact chromosomes 13, 12, 9, and 15. Myelemia was associated with an adverse prognosis. We categorized chemotherapeutic regimens into 5 groups: acute myeloid leukemia (AML)-like, acute lymphoid leukemia (ALL)-like, lymphoma (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP])-like, high-dose methotrexate with asparaginase (Aspa-MTX) chemotherapies, and not otherwise specified (NOS) treatments. Thirty patients received allogeneic hematopoietic cell transplantation (allo-HCT), and 4 patients received autologous hematopoietic cell transplantation. There was no difference in survival between patients receiving AML-like, ALL-like, or Aspa-MTX regimens; survival was longer in patients who received AML-like, ALL-like, or Aspa-MTX regimens than in those who received CHOP-like regimens or NOS. Eleven patients are in persistent complete remission after allo-HCT with a median survival of 49 months vs 8 for other patients. Our series confirms a high response rate with a lower toxicity profile with the Aspa-MTX regimen, offering the best chance of access to hematopoietic cell transplantation and a possible cure., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
116. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
- Author
-
Salles G, Bachy E, Smolej L, Simkovic M, Baseggio L, Panovska A, Besson H, Healy N, Garside J, Iraqi W, Diels J, Pick-Lauer C, Spacek M, Urbanova R, Lysak D, Hermans R, Lundbom J, Callet-Bauchu E, and Doubek M
- Subjects
- Adenine analogs & derivatives, Adult, Aged, Aged, 80 and over, Bendamustine Hydrochloride administration & dosage, Cyclophosphamide administration & dosage, Disease-Free Survival, Female, Humans, Male, Middle Aged, Piperidines, Rituximab administration & dosage, Survival Rate, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Databases, Factual, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Pyrazoles administration & dosage, Pyrimidines administration & dosage
- Abstract
After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards model, adjusted for differences in baseline characteristics. Rituximab-containing regimens were often prescribed in clinical practice. The most frequently prescribed regimens were fludarabine + cyclophosphamide + rituximab (FCR, 29.3%), bendamustine + rituximab (BR, 17.7%), and other rituximab-containing regimens (22.0%) in the treatment-naïve setting (n = 604), other non-FCR/BR rituximab-containing regimens (38.7%) and non-rituximab-containing regimens (28.5%) in the relapsed/refractory setting (n = 945). Adjusted HRs (95% CI) for progression-free survival (PFS) and overall survival (OS), respectively, with ibrutinib versus real-world regimens were 0.23 (0.14-0.37; p < 0.0001) and 0.40 (0.22-0.76; p = 0.0048) in the treatment-naïve setting, and 0.21 (0.16-0.27; p < 0.0001) and 0.29 (0.21-0.41; p < 0.0001) in the relapsed/refractory setting. When comparing real-world use of ibrutinib (n = 53) versus other real-world regimens in relapsed/refractory CLL (objective 3), adjusted HRs (95% CI) were 0.37 (0.22-0.63; p = 0.0003) for PFS and 0.53 (0.27-1.03; p < 0.0624) for OS. This adjusted analysis, based on nonrandomized patient data, suggests ibrutinib to be more effective than other commonly used regimens for CLL.
- Published
- 2019
- Full Text
- View/download PDF
117. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
- Author
-
Chapiro E, Pramil E, Diop M, Roos-Weil D, Dillard C, Gabillaud C, Maloum K, Settegrana C, Baseggio L, Lesesve JF, Yon M, Jondreville L, Lesty C, Davi F, Le Garff-Tavernier M, Droin N, Dessen P, Algrin C, Leblond V, Gabarre J, Bouzy S, Eclache V, Gaillard B, Callet-Bauchu E, Muller M, Lefebvre C, Nadal N, Ittel A, Struski S, Collonge-Rame MA, Quilichini B, Fert-Ferrer S, Auger N, Radford-Weiss I, Wagner L, Scheinost S, Zenz T, Susin SA, Bernard OA, and Nguyen-Khac F
- Subjects
- Aged, Aged, 80 and over, Chromosome Aberrations, Cytogenetic Analysis, Female, Humans, Male, Middle Aged, Prognosis, Leukemia, Prolymphocytic, B-Cell genetics, Proto-Oncogene Proteins c-myc genetics, Tumor Suppressor Protein p53 genetics
- Abstract
B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechanisms are poorly understood. Our cytogenetic and molecular assessments of 34 patients with B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype was complex (≥3 abnormalities) in 73% of the patients and highly complex (≥5 abnormalities) in 45%. The most frequent chromosomal aberrations were translocations involving MYC [t(MYC)] (62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p (23%). Twenty-six (76%) of the 34 patients exhibited an MYC aberration, resulting from mutually exclusive translocations or gains. Whole-exome sequencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, SETD2, CHD2, CXCR4, and BCLAF1. The majority of B-PLL used the IGHV3 or IGHV4 subgroups (89%) and displayed significantly mutated IGHV genes (79%). We identified 3 distinct cytogenetic risk groups: low risk (no MYC aberration), intermediate risk (MYC aberration but no del17p), and high risk (MYC aberration and del17p) (P = .0006). In vitro drug response profiling revealed that the combination of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodomain and extra-terminal motif inhibitor targeting MYC) was associated with significantly lower viability of B-PLL cells harboring a t(MYC). We concluded that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting MYC may be a useful treatment option in this disease., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
118. Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort.
- Author
-
Degaud M, Baseggio L, Grange B, Manzoni D, Huet S, Callet-Bauchu E, Traverse-Glehen A, Davi F, Ghesquières H, Salles G, and Sujobert P
- Abstract
According to the World Health Organization (WHO) classification, the nosology of B-cell neoplasms integrates clinical, morphological, phenotypic, and genetic data. In this retrospective analysis, we identified 18 patients with isolated neoplastic lymphocytosis that could not be accurately classified within the WHO classification. Most of them were asymptomatic at the time of diagnosis and the evolution was relatively indolent, as only five patients required treatment after a median follow-up of 48 months. The neoplastic B-cells expressed CD5 in most cases, but the Royal Marsden Hospital score was strictly below 3. Trisomy 12 was the most frequent cytogenetic abnormality. High-throughput sequencing highlighted mutations found in both chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). Similarly, the immunoglobulin heavy chain variable region repertoire was distinct from those reported in CLL or MZL. However, as treatment choice is dependent on the correct classification of the lymphoproliferative disorder, a histological diagnosis should be performed in case patients need to be treated., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
119. Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.
- Author
-
Solly F, Angelot-Delettre F, Ticchioni M, Geneviève F, Rambaud H, Baseggio L, Plesa A, Debliquis A, Garnache-Ottou F, Roggy A, Campos L, Aanei C, Rosenthal-Allieri A, Georget MT, Lachot S, Jacob MC, Robillard N, Wuilleme S, Andre-Kerneis E, Cornet E, Salaun V, Bennami H, Lhoumeau AC, Arnoulet C, Jacqmin H, Neyman N, Latger-Cannard V, Massin F, Lainey E, Le Garff-Tavernier M, Costopoulos M, Roussel M, Mayeur-Rousse C, Eischen A, Raggeneau V, Derrieux C, Maurer M, Asnafi V, Trinquand A, Brouzes C, and Lhermitte L
- Subjects
- Belgium, Flow Cytometry instrumentation, Flow Cytometry standards, Fluorescence, France, Hematologic Neoplasms blood, Humans, Immunophenotyping methods, Lymphocytes cytology, Lymphocytes metabolism, Monocytes cytology, Monocytes metabolism, Quality Control, Reference Standards, Reproducibility of Results, Flow Cytometry methods, Hematologic Neoplasms diagnosis, Immunophenotyping standards
- Abstract
Flow cytometry is broadly used for the identification, characterization, and monitoring of hematological malignancies. However, the use of clinical flow cytometry is restricted by its lack of reproducibility across multiple centers. Since 2006, the EuroFlow consortium has been developing a standardized procedure detailing the whole process from instrument settings to data analysis. The FranceFlow group was created in 2010 with the intention to educate participating centers in France about the standardized instrument setting protocol (SOP) developed by the EuroFlow consortium and to organise several rounds of quality controls (QCs) in order to evaluate the feasibility of its application and its results. Here, we report the 5 year experience of the FranceFlow group and the results of the seven QCs of 23 instruments, involving up to 19 centers, in France and in Belgium. The FranceFlow group demonstrates that both the distribution and applicability of the SOP have been successful. Intercenter reproducibility was evaluated using both normal and pathological blood samples. Coefficients of variation (CVs) across the centers were <7% for the percentages of cell subsets and <30% for the median fluorescence intensities (MFIs) of the markers tested. Intracenter reproducibility provided similar results with CVs of <3% for the percentages of the majority of cell subsets, and CVs of <20% for the MFI values for the majority of markers. Altogether, the FranceFlow group show that the 19 participating labs might be considered as one unique laboratory with 23 identical flow cytometers able to reproduce identical results. Therefore, SOP significantly improves reproducibility of clinical flow in hematology and opens new avenues by providing a robust companion diagnostic tool for clinical trials in hematology. © 2019 International Society for Advancement of Cytometry., (© 2019 International Society for Advancement of Cytometry.)
- Published
- 2019
- Full Text
- View/download PDF
120. Breast implant-associated anaplastic large cell lymphoma.
- Author
-
Baseggio L, Travers-Glehen A, Bachy E, and Laurent C
- Published
- 2019
- Full Text
- View/download PDF
121. One translocation for 2 lymphoid neoplasms.
- Author
-
Aussedat G and Baseggio L
- Subjects
- Aged, B-Lymphocytes metabolism, Humans, Lymphoma, Mantle-Cell pathology, Male, Multiple Myeloma pathology, Neoplasms, Multiple Primary pathology, B-Lymphocytes pathology, Chromosomes, Human, Pair 11 genetics, Chromosomes, Human, Pair 14 genetics, Lymphoma, Mantle-Cell genetics, Multiple Myeloma genetics, Neoplasms, Multiple Primary genetics, Translocation, Genetic
- Published
- 2019
- Full Text
- View/download PDF
122. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
- Author
-
Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, and Thieblemont C
- Subjects
- Adult, Aged, Bendamustine Hydrochloride administration & dosage, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Lymphoma, B-Cell, Marginal Zone mortality, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Rituximab administration & dosage, Splenectomy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, B-Cell, Marginal Zone drug therapy, Splenic Neoplasms drug therapy
- Abstract
Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revision were treated with bendamustine (90 mg/m
2 days 1, 2) and rituximab (375 mg/m2 day 1) every 28 days for six cycles (B-R). The overall response and CR rates were 91% and 73%, respectively. Duration of response, progression-free survival and overall survival at 3 years were 93% (95% confidence interval [CI] 81-98), 90% (95% CI 77-96) and 96% (95% CI 84-98), respectively. Toxicity was mostly haematological. Neutropenia grade ≥3 was recorded in 43% of patients; infections and febrile neutropenia in 5·4% and 3·6%. Overall, 14 patients (25%) experienced serious adverse events. Five patients (9%) went off-study because of toxicity and one patient died from infection. In conclusion, B-R resulted in a very effective first-line regimen for SMZL. Based on the results achieved in the BRISMA trial, B-R should be considered when a chemotherapy combination with rituximab is deemed necessary for symptomatic SMZL patients., (© 2018 British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
123. Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma.
- Author
-
Verney A, Traverse-Glehen A, Callet-Bauchu E, Jallades L, Magaud JP, Salles G, Genestier L, and Baseggio L
- Abstract
In splenic marginal zone lymphoma (SMZL), specific and functional Toll-like Receptor (TLR) patterns have been recently described, suggesting their involvement in tumoral proliferation. Splenic diffuse red pulp lymphoma with villous lymphocytes (SDRPL) is close to but distinct from SMZL, justifying here the comparison of TLR patterns and functionality in both entities. Distinct TLR profiles were observed in both lymphoma subtypes. SDRPL B cells showed higher expression of TLR7 and to a lesser degree TLR9, in comparison to SMZL B cells. In both entities, TLR7 and TLR9 pathways appeared functional, as shown by IL-6 production upon TLR7 and TLR9 agonists stimulations. Interestingly, circulating SDRPL, but not SMZL B cells, constitutively expressed CD86. In addition, stimulation with both TLR7 and TLR9 agonists significantly increased CD80 expression in circulating SDRPL but not SMZL B cells. Finally, TLR7 and TLR9 stimulations had no impact on proliferation and apoptosis of SMZL or SDRPL B cells. In conclusion, SMZL and SDRPL may derive from different splenic memory B cells with specific immunological features that can be used as diagnosis markers in the peripheral blood., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
124. A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN TM analyzers in routine laboratory practice.
- Author
-
Schillinger F, Sourdeau E, Boubaya M, Baseggio L, Clauser S, Cornet E, Debord C, Defour JP, Dubois F, Eveillard M, Galoisy AC, Geay MO, Mullier F, Nivaggioni V, Soenen V, Morel P, Garnache-Ottou F, Ronez E, Bardet V, and Deconinck E
- Subjects
- Adult, Aged, Aged, 80 and over, Automation, Laboratory, Blood Cell Count, Cohort Studies, Female, Humans, Leukemia, Myelomonocytic, Chronic pathology, Leukocytosis pathology, Logistic Models, Male, Middle Aged, Multivariate Analysis, Leukemia, Myelomonocytic, Chronic diagnosis, Leukocytosis diagnosis, Lymphocytes pathology, Monocytes pathology, Neutrophils pathology
- Abstract
According to WHO recommendations, diagnosis of chronic myelomonocytic leukemia (CMML) beforehand requires microscopic examination of peripheral blood to identify dysplasia and/or blasts when monocytes are greater or equal to 1.0 × 10
9 /L and 10% of leucocytes. We analyzed parameters derived from SysmexTM XN analyzers to improve the management of microscopic examination for monocytosis. We analyzed results of the complete blood count and the positioning and dispersion parameters of polymorphonuclear neutrophils and monocytes in 61 patients presenting with CMML and 635 control patients presenting with a reactive monocytosis. We used logistic regression and multivariate analysis to define a score for smear review. Three parameters were selected: neutrophil/monocyte ratio, structural neutrophil dispersion (Ne-WX) and monocyte absolute value. We established an equation in which the threshold of 0.160 guided microscopic examination in the search for CMML abnormalities with a sensitivity of 0.967 and a specificity of 0.978 in the learning cohort (696 samples) and 0.923 and 0.936 in the validation cohort (1809 samples) respectively. We created a score for microscopic smear examination of patients presenting with a monocytosis greater or equal to 1.0 × 109 /L and 10% of leucocytes, improving efficiency in laboratory routine practice.- Published
- 2018
- Full Text
- View/download PDF
125. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
- Author
-
Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, and Salles G
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials, Phase III as Topic, Female, Humans, Internationality, Maintenance Chemotherapy, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Predictive Value of Tests, Progression-Free Survival, Proportional Hazards Models, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Assessment methods, Rituximab administration & dosage, Gene Expression Profiling, Lymphoma, Follicular drug therapy, Lymphoma, Follicular genetics, RNA, Neoplasm analysis
- Abstract
Background: Patients with follicular lymphoma have heterogeneous outcomes. Predictor models to distinguish, at diagnosis, between patients at high and low risk of progression are needed. The objective of this study was to use gene-expression profiling data to build and validate a predictive model of outcome for patients treated in the rituximab era., Methods: A training set of fresh-frozen tumour biopsies was prospectively obtained from 160 untreated patients with high-tumour-burden follicular lymphoma enrolled in the phase 3 randomised PRIMA trial, in which rituximab maintenance was evaluated after rituximab plus chemotherapy induction (median follow-up 6·6 years [IQR 6·0-7·0]). RNA of sufficient quality was obtained for 149 of 160 cases, and Affymetrix U133 Plus 2.0 microarrays were used for gene-expression profiling. We did a multivariate Cox regression analysis to identify genes with expression levels associated with progression-free survival independently of maintenance treatment in a subgroup of 134 randomised patients. Expression levels from 95 curated genes were then determined by digital expression profiling (NanoString technology) in 53 formalin-fixed paraffin-embedded samples of the training set to compare the technical reproducibility of expression levels for each gene between technologies. Genes with high correlation (>0·75) were included in an L2-penalised Cox model adjusted on rituximab maintenance to build a predictive score for progression-free survival. The model was validated using NanoString technology to digitally quantify gene expression in 488 formalin-fixed, paraffin-embedded samples from three independent international patient cohorts from the PRIMA trial (n=178; distinct from the training cohort), the University of Iowa/Mayo Clinic Lymphoma SPORE project (n=201), and the Barcelona Hospital Clinic (n=109). All tissue samples consisted of pretreatment diagnostic biopsies and were confirmed as follicular lymphoma grade 1-3a. The patients were all treated with regimens containing rituximab and chemotherapy, possibly followed by either rituximab maintenance or ibritumomab-tiuxetan consolidation. We determined an optimum threshold on the score to predict patients at low risk and high risk of progression. The model, including the multigene score and the threshold, was initially evaluated in the three validation cohorts separately. The sensitivity and specificity of the score for the prediction of the risk of lymphoma progression at 2 years were assessed on the combined validation cohorts., Findings: In the training cohort, the expression levels of 395 genes were associated with a risk of progression. 23 genes reflecting both B-cell biology and tumour microenvironment with correlation coefficients greater than 0·75 between the two technologies and sample types were retained to build a predictive model that identified a population at an increased risk of progression (p<0·0001). In a multivariate Cox model for progression-free survival adjusted on rituximab maintenance treatment and Follicular Lymphoma International Prognostic Index 1 (FLIPI-1) score, this predictor independently predicted progression (adjusted hazard ratio [aHR] of the high-risk group compared with the low-risk group 3·68, 95% CI 2·19-6·17 [p<0·0001]). The 5-year progression-free survival was 26% (95% CI 16-43) in the high-risk group and 73% (64-83) in the low-risk group. The predictor performances were confirmed in each of the individual validation cohorts (aHR comparing high-risk to low-risk groups 2·57 [95% CI 1·65-4·01] in cohort 1; 2·12 [1·32-3·39] in cohort 2; and 2·11 [1·01-4·41] in cohort 3). In the combined validation cohort, the median progression-free survival was 3·1 years (95% CI 2·4-4·8) in the high-risk group and 10·8 years (10·1-not reached) in the low-risk group (p<0·0001). The risk of lymphoma progression at 2 years was 38% (95% CI 29-46) in the high-risk group and 19% (15-24) in the low-risk group. In a multivariate analysis, the score predicted progression-free survival independently of anti-CD20 maintenance treatment and of the FLIPI score (aHR for the combined cohort 2·30, 95% CI 1·72-3·07)., Interpretation: We developed and validated a robust 23-gene expression-based predictor of progression-free survival that is applicable to routinely available formalin-fixed, paraffin-embedded tumour biopsies from patients with follicular lymphoma at time of diagnosis. Applying this score could allow individualised therapy for patients according to their risk category., Funding: Roche, SIRIC Lyric, LYSARC, National Institutes of Health, the Henry J Predolin Foundation, and the Spanish Plan Nacional de Investigacion., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
126. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2 , TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.
- Author
-
Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles G, and Traverse-Glehen A
- Subjects
- Aged, Aged, 80 and over, Chromosome Aberrations, DNA Copy Number Variations, Female, Humans, Kruppel-Like Transcription Factors genetics, Leukemia, Hairy Cell diagnosis, Leukemia, Hairy Cell genetics, Lymphoma, B-Cell, Marginal Zone diagnosis, Lymphoma, B-Cell, Marginal Zone genetics, Middle Aged, Mutation, Myeloid Differentiation Factor 88 genetics, Tumor Necrosis Factor alpha-Induced Protein 3 genetics, Exome Sequencing, Biomarkers, Tumor, Genetic Variation, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell genetics, Proto-Oncogene Proteins genetics, Repressor Proteins genetics, Splenic Neoplasms diagnosis, Splenic Neoplasms genetics
- Abstract
Splenic diffuse red pulp lymphoma is an indolent small B-cell lymphoma recognized as a provisional entity in the World Health Organization 2008 classification. Its precise relationship to other related splenic B-cell lymphomas with frequent leukemic involvement or other lymphoproliferative disorders remains undetermined. We performed whole-exome sequencing to explore the genetic landscape of ten cases of splenic diffuse red pulp lymphoma using paired tumor and normal samples. A selection of 109 somatic mutations was then evaluated in a cohort including 42 samples of splenic diffuse red pulp lymphoma and compared to those identified in 46 samples of splenic marginal zone lymphoma and eight samples of hairy-cell leukemia. Recurrent mutations or losses in BCOR (the gene encoding the BCL6 corepressor) - frameshift (n=3), nonsense (n=2), splicing site (n=1), and copy number loss (n=4) - were identified in 10/42 samples of splenic diffuse red pulp lymphoma (24%), whereas only one frameshift mutation was identified in 46 cases of splenic marginal zone lymphoma (2%). Inversely, KLF2 , TNFAIP3 and MYD88 , common mutations in splenic marginal zone lymphoma, were rare (one KLF2 mutant in 42 samples; 2%) or absent ( TNFAIP3 and MYD88 ) in splenic diffuse red pulp lymphoma. These findings define an original genetic profile of splenic diffuse red pulp lymphoma and suggest that the mechanisms of pathogenesis of this lymphoma are distinct from those of splenic marginal zone lymphoma and hairy-cell leukemia., (Copyright© 2017 Ferrata Storti Foundation.)
- Published
- 2017
- Full Text
- View/download PDF
127. Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes.
- Author
-
Tesson B, Huet S, Grange B, Jallades L, Baseggio L, Felman P, Traverse-Glehen A, Magaud JP, Lega JC, Bole-Feysot C, Salles G, Callet-Bauchu E, and Sujobert P
- Subjects
- Adult, Cell Nucleus ultrastructure, Cell Separation, Clone Cells ultrastructure, Disease Progression, Female, HLA-DR7 Antigen analysis, Humans, Immunoglobulin M blood, Lymphocytosis pathology, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Precancerous Conditions pathology, Smoking, Exome Sequencing, B-Lymphocytes ultrastructure, Lymphocytosis genetics, Mutation, Precancerous Conditions genetics
- Published
- 2017
- Full Text
- View/download PDF
128. The Genetic Basis of Hepatosplenic T-cell Lymphoma.
- Author
-
McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, and Davé SS
- Subjects
- ATPases Associated with Diverse Cellular Activities, Adolescent, Adult, Aged, Base Sequence, Child, Child, Preschool, DNA-Binding Proteins, Enhancer of Zeste Homolog 2 Protein, Exome genetics, Female, Humans, Liver Neoplasms complications, Liver Neoplasms pathology, Lymphoma, T-Cell complications, Lymphoma, T-Cell pathology, Male, Middle Aged, Proto-Oncogene Proteins p21(ras), Splenic Neoplasms complications, Splenic Neoplasms pathology, Transcription Factors, Tumor Suppressor Proteins genetics, Young Adult, DNA Helicases genetics, Histone-Lysine N-Methyltransferase genetics, Liver Neoplasms genetics, Lymphoma, T-Cell genetics, Splenic Neoplasms genetics, Tumor Suppressor Protein p53 genetics
- Abstract
Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68 HSTLs, we define recurrently mutated driver genes and copy-number alterations in the disease. Chromatin-modifying genes, including SETD2, INO80 , and ARID1B , were commonly mutated in HSTL, affecting 62% of cases. HSTLs manifest frequent mutations in STAT5B (31%), STAT3 (9%), and PIK3CD (9%), for which there currently exist potential targeted therapies. In addition, we noted less frequent events in EZH2, KRAS , and TP53 SETD2 was the most frequently silenced gene in HSTL. We experimentally demonstrated that SETD2 acts as a tumor suppressor gene. In addition, we found that mutations in STAT5B and PIK3CD activate critical signaling pathways important to cell survival in HSTL. Our work thus defines the genetic landscape of HSTL and implicates gene mutations linked to HSTL pathogenesis and potential treatment targets. Significance: We report the first systematic application of whole-exome sequencing to define the genetic basis of HSTL, a rare but lethal disease. Our work defines SETD2 as a tumor suppressor gene in HSTL and implicates genes including INO80 and PIK3CD in the disease. Cancer Discov; 7(4); 369-79. ©2017 AACR. See related commentary by Yoshida and Weinstock, p. 352 This article is highlighted in the In This Issue feature, p. 339 ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
129. Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.
- Author
-
Traverse-Glehen A, Verney A, Gazzo S, Jallades L, Chabane K, Hayette S, Coiffier B, Callet-Bauchu E, Ffrench M, Felman P, Berger F, Baseggio L, and Salles G
- Subjects
- Aged, Aged, 80 and over, Antigens, CD genetics, Antigens, CD metabolism, Biomarkers, Tumor, Chromosome Aberrations, DNA Mutational Analysis, Female, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Immunophenotyping, In Situ Hybridization, Fluorescence, Lymph Nodes metabolism, Lymph Nodes pathology, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell metabolism, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Splenic Neoplasms diagnosis, Splenic Neoplasms metabolism, Lymphoma, B-Cell genetics, Mutation, Splenic Neoplasms genetics
- Abstract
Splenic Diffuse Red Pulp Lymphoma (SDRPL) has been recently introduced as a provisional entity but differential diagnosis with other splenic lymphomas is needed to be clarified since the therapeutic approaches are distinct. Recently described recurrent mutations or CD180 expression appear useful for differential diagnosis. We completed our previous description in a larger cohort including 53 patients selected on the presence of characteristic villous cells in peripheral blood (PB) and a specific immunophenotype. Immunoglobulin heavy variable (IGHV), BRAF, MYD88, and NOTCH2 mutations were determined and CD180 and BRAF expressions were assessed. Most cases (79%) were IGHV mutated with an overrepresentation of IGHV3-23 (19%) and IGHV4-34 (21%). MYD88 L265P and NOTCH2 mutations were observed in one case each, whereas no BRAF V600E mutation or expression was found. All cases demonstrated a high CD180 expression. Those results strengthen the concept that SDRPL does emerge as a new lymphoma entity distinct from the other splenic lymphomas with circulating lymphocytes.
- Published
- 2017
- Full Text
- View/download PDF
130. Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations.
- Author
-
Curiel-Olmo S, Mondéjar R, Almaraz C, Mollejo M, Cereceda L, Marès R, Derdak S, Campos-Martín Y, Batlle A, González de Villambrosía S, Gut M, Blanc J, Traverse-Glehen A, Verney A, Baseggio L, Camacho FI, Wotherspoon A, Stamatopoulos K, Xochelli A, Papadaki T, Kanellis G, Ponzoni M, García-Cosío M, Vaqué JP, Beltrán S, Gut I, Piris MA, and Martínez N
- Subjects
- Gene Expression, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Lymphoma, B-Cell pathology, Splenic Neoplasms pathology, Cyclin D3 genetics, Cyclin D3 metabolism, Lymphoma, B-Cell genetics, Lymphoma, B-Cell metabolism, Mutation, Splenic Neoplasms genetics, Splenic Neoplasms metabolism
- Published
- 2017
- Full Text
- View/download PDF
131. Ibrutinib-Induced Lymphocytosis: Cytological Features.
- Author
-
Quintela A, Sujobert P, Callet-Bauchu E, Salles G, and Baseggio L
- Subjects
- Adenine analogs & derivatives, Agammaglobulinaemia Tyrosine Kinase, Aged, Aged, 80 and over, Female, Gene Expression, Humans, Leukemia, Lymphocytic, Chronic, B-Cell enzymology, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Lymphocyte Count, Lymphocytosis chemically induced, Lymphocytosis pathology, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases antagonists & inhibitors, Protein-Tyrosine Kinases metabolism, Antineoplastic Agents therapeutic use, Chromosome Aberrations, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Lymphocytosis diagnosis, Protein Kinase Inhibitors therapeutic use, Pyrazoles therapeutic use, Pyrimidines therapeutic use
- Published
- 2017
- Full Text
- View/download PDF
132. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
- Author
-
Manzoni D, Catallo R, Chebel A, Baseggio L, Michallet AS, Roualdes O, Magaud JP, Salles G, and Ffrench M
- Subjects
- Adenine analogs & derivatives, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal pharmacology, Apoptosis drug effects, Cell Cycle drug effects, DNA Damage drug effects, Drug Synergism, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Male, Middle Aged, Piperidines, Stress, Physiological drug effects, Tumor Cells, Cultured, B-Lymphocytes drug effects, Cell Proliferation drug effects, Dexamethasone pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Pyrazoles pharmacology, Pyrimidines pharmacology
- Abstract
New B-cell receptor-targeted therapies such as ibrutinib, a Bruton tyrosine kinase inhibitor, are now proposed for lymphoid pathologies. The putative benefits of its combination with glucocorticoids were evaluated here. We compared the effects of dexamethasone (DXM), ibrutinib and their in vitro combination on proliferation and metabolic stress markers in stimulated normal B-lymphocytes and in malignant lymphocytes from chronic lymphocytic leukemia (CLL) patients. In both cellular models, cell cycle progression was globally inhibited by DXM and/or ibrutinib. This inhibition was significantly amplified by DXM addition to ibrutinib and was related to a significant decrease in the expression of the cell cycle regulatory proteins CDK4 and cyclin E. Apoptosis increased especially with DXM/ibrutinib combination and was associated with a significant decrease in Mcl-1 expression. Treatment effects on metabolic stress were evaluated by DNA damage recognition after 53BP1 foci labeling. The percentage of cells with more than five 53BP1 foci decreased significantly with ibrutinib in normal and CLL lymphocytes. This decrease was strongly reinforced, in CLL, by DXM addition. Our data indicated that, in vitro, DXM potentiated antiproliferative effects of ibrutinib and decreased DNA damage in lymphoid B-cells. Thus their combination may be proposed for CLL treatment., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
133. CD1d-restricted peripheral T cell lymphoma in mice and humans.
- Author
-
Bachy E, Urb M, Chandra S, Robinot R, Bricard G, de Bernard S, Traverse-Glehen A, Gazzo S, Blond O, Khurana A, Baseggio L, Heavican T, Ffrench M, Crispatzu G, Mondière P, Schrader A, Taillardet M, Thaunat O, Martin N, Dalle S, Le Garff-Tavernier M, Salles G, Lachuer J, Hermine O, Asnafi V, Roussel M, Lamy T, Herling M, Iqbal J, Buffat L, Marche PN, Gaulard P, Kronenberg M, Defrance T, and Genestier L
- Subjects
- Animals, Antigens, CD1d genetics, Antigens, Ly genetics, Antigens, Ly immunology, Female, Humans, Lymphoma, T-Cell, Peripheral genetics, Lymphoma, T-Cell, Peripheral pathology, Male, Mice, Mice, Knockout, NK Cell Lectin-Like Receptor Subfamily B genetics, NK Cell Lectin-Like Receptor Subfamily B immunology, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell immunology, Signal Transduction genetics, Streptococcus pneumoniae immunology, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 immunology, Antigens, CD1d immunology, Lymphoma, T-Cell, Peripheral immunology, Signal Transduction immunology
- Abstract
Peripheral T cell lymphomas (PTCLs) are a heterogeneous entity of neoplasms with poor prognosis, lack of effective therapies, and a largely unknown pathophysiology. Identifying the mechanism of lymphomagenesis and cell-of-origin from which PTCLs arise is crucial for the development of efficient treatment strategies. In addition to the well-described thymic lymphomas, we found that p53-deficient mice also developed mature PTCLs that did not originate from conventional T cells but from CD1d-restricted NKT cells. PTCLs showed phenotypic features of activated NKT cells, such as PD-1 up-regulation and loss of NK1.1 expression. Injections of heat-killed Streptococcus pneumonia, known to express glycolipid antigens activating NKT cells, increased the incidence of these PTCLs, whereas Escherichia coli injection did not. Gene expression profile analyses indicated a significant down-regulation of genes in the TCR signaling pathway in PTCL, a common feature of chronically activated T cells. Targeting TCR signaling pathway in lymphoma cells, either with cyclosporine A or anti-CD1d blocking antibody, prolonged mice survival. Importantly, we identified human CD1d-restricted lymphoma cells within Vδ1 TCR-expressing PTCL. These results define a new subtype of PTCL and pave the way for the development of blocking anti-CD1d antibody for therapeutic purposes in humans., (© 2016 Bachy et al.)
- Published
- 2016
- Full Text
- View/download PDF
134. An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter's Syndrome.
- Author
-
Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C, Baseggio L, Subtil F, Salles G, Dupuis JM, and Conte MJ
- Subjects
- Biomarkers, Biopsy, Disease Progression, Humans, Neoplasm Staging, Positron Emission Tomography Computed Tomography, ROC Curve, Fluorodeoxyglucose F18, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Positron-Emission Tomography
- Published
- 2016
- Full Text
- View/download PDF
135. [Combined variable immunodeficiency with unusal features. A case report].
- Author
-
De Charry F, Peterschmitt Tonetti A, De Charry C, Baseggio L, Pasquet F, Khenifer S, Rassat R, and Pavic M
- Subjects
- Common Variable Immunodeficiency diagnostic imaging, Common Variable Immunodeficiency pathology, Female, Granuloma diagnostic imaging, Granuloma pathology, Humans, Lung Diseases, Interstitial diagnostic imaging, Lung Diseases, Interstitial pathology, Middle Aged, Radiography, Thoracic, Common Variable Immunodeficiency complications, Granuloma etiology, Lung Diseases, Interstitial etiology
- Abstract
Introduction: The association granulomatosis - combined variable immunodeficiency (CVID) - is well known from the clinicians. However, the association with a large granular lymphocyte (LGL) leukemia has not been yet reported., Case Report: We report a 50-year-old woman, followed for CVID associated with a granulomatous disease. During the follow-up, the patient developed a granulomatous lymphocytic interstitiel lung disease (GLILD). Secondarily, she presented a LGL leukemia., Conclusion: To our knowledge, this is the first reported case of an association between CVID and LGL leukemia., (Copyright © 2014 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
136. Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells.
- Author
-
Brisou G, Manzoni D, Dalle S, Felman P, Morel D, Boubaya M, Magaud JP, and Baseggio L
- Subjects
- Autoanalysis, B-Lymphocytes pathology, Blood Cell Count, Cell Nucleus pathology, Cytoplasm pathology, Diagnosis, Differential, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell blood, Male, Middle Aged, Hematologic Tests instrumentation, Sezary Syndrome blood, T-Lymphocytes pathology
- Abstract
Background: The rigorous cytological review by manual or automatic microscopic analysis is critical in the detection of circulating neoplastic cells, since their morphology as well as their count contributes to the diagnosis and prognosis of many diseases. However, the cytological analysis is not always obvious and requires trained and competent cytologist. In this context, the alarms and/or parameters generated by hematology analyzer could be particularly informative to alert the operators., Methods: Blood samples from patients with Sezary syndrome (n = 9) were studied with Sysmex XN-1000 analyzer, and compared to patients with benign or tumoral skin lesions (n = 47) and patients with chronic lymphoproliferative B-cell diseases (n = 51) used as control., Results: In present series, the value of structural lymphoid parameters (LyX and LyZ) and the alarm Blast/Abn Lympho were statistically higher in Sezary cases than in control cases. In addition, the value of LyX was associated to the count of circulating Sezary cells and value of LyZ to the presence of large Sezary cells, both parameters described as prognostic factors., Conclusion: The combination of alarm Blast/Abn Lympho and structural parameters (Ly-X/Ly-Z/Ly-Y) may allow to define rule of blood slide review to screen circulating Sezary cells, and give promising results in B-cell diseases., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
137. Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management.
- Author
-
Rossi C, Brisou G, Baseggio L, Roch J, Safar V, Karlin L, Sesques P, Bouafia-Sauvy F, Lebras L, Coiffier B, Salles G, and Michallet AS
- Subjects
- Antineoplastic Combined Chemotherapy Protocols, Brain pathology, Humans, Immunohistochemistry, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Invasiveness, Spinal Cord pathology, Treatment Outcome, Central Nervous System pathology, Leukemia, Lymphocytic, Chronic, B-Cell pathology
- Published
- 2014
- Full Text
- View/download PDF
138. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
- Author
-
Lenglet J, Traullé C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S, Noguera ME, Traverse-Glehen A, Ffrench M, Baseggio L, Felman P, Callet-Bauchu E, Brice P, Berger F, Salles G, Brière J, Coiffier B, and Thieblemont C
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Follow-Up Studies, Humans, Immunophenotyping, Lymphoma, B-Cell, Marginal Zone diagnosis, Lymphoma, B-Cell, Marginal Zone mortality, Lymphoma, B-Cell, Marginal Zone therapy, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prognosis, Risk Factors, Splenic Neoplasms diagnosis, Splenic Neoplasms mortality, Splenic Neoplasms therapy, Treatment Outcome, Lymphoma, B-Cell, Marginal Zone surgery, Splenectomy, Splenic Neoplasms surgery
- Abstract
Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line treatment. At 6 months, all patients but three recovered from all cytopenias. The median lymphocyte count at 6 months and 1 year was 11.51 × 10(9)/L and 6.9 × 10(9)/L, respectively. Median progression-free survival (PFS) was 8.25 years. The 5-year and 10-year overall survival (OS) rates were 84% and 67%, respectively. Histological transformation occurred in 11% of patients, and was the only parameter significantly associated with a shorter time to progression (p = 0.0001). Significant prognostic factors for OS were age (p = 0.0356) and histological transformation (p = 0.0312). In this large retrospective cohort, we confirmed that splenectomy as first-line treatment in patients with SMZL corrected cytopenias and lymphocytosis within the first year and was associated with a good PFS.
- Published
- 2014
- Full Text
- View/download PDF
139. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
- Author
-
Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, and Salles G
- Subjects
- Aged, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Disease Progression, Female, Humans, Lymphoma, Follicular diagnosis, Lymphoma, Follicular drug therapy, Lymphoma, Follicular pathology, Male, Middle Aged, Neoplastic Cells, Circulating pathology, Prognosis, Rare Diseases etiology, Retrospective Studies, Rituximab, Severity of Illness Index, Survival Analysis, Treatment Outcome, Leukocytosis etiology, Lymphoma, Follicular complications
- Abstract
Follicular Lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) subtype and its course is heterogeneous. At diagnosis, some patients with FL manifest a detectable leukaemic phase (FL-LP), but this feature has been seldom described and is poorly characterized. Among 499 patients diagnosed with FL in Lyon-Sud hospital, 37 (7·4%) had characteristic FL-LP (by cytological blood smears and flow cytometric analysis). In addition, 91/1135 FL patients from the PRIMA study presented FL-LP at study entry. In order to evaluate the outcome of this Lyon-Sud cohort, FL-LP patients were matched with 111 newly diagnosed FL without LP according to the Follicular Lymphoma International Prognostic Index (FLIPI) score, age and treatment. Presence of FL-LP was associated with shorter progression-free survival (PFS) and overall survival (OS) (P = 0·004 and P = 0·031, respectively). Presence of FL-LP and high FLIPI score remained independent prognostic factors in a Cox model for time to progression (TTP). A number of circulating lymphoma cells (CLC) >4 × 10(9) /l was the most significant predictor for a shorter TTP in this Cox model. The prognostic impact of FL-LP on TTP was validated in the PRIMA cohort (P = 0·0004). In conclusion, FL-LP is a rare event associated with shorter PFS and patients with CLC >4 × 10(9) /l have a poorer outcome. These patients should be monitored carefully to consider alternative therapeutic options., (© 2013 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
140. Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study.
- Author
-
Solly F, Rigollet L, Baseggio L, Guy J, Borgeot J, Guérin E, Debliquis A, Drenou B, Campos L, Lacombe F, and Béné MC
- Subjects
- Calibration, Flow Cytometry standards, Fluorescent Dyes chemistry, GPI-Linked Proteins metabolism, Humans, Neutrophils metabolism, Receptors, IgG metabolism, Reference Standards, Staining and Labeling, Flow Cytometry methods
- Abstract
Flow cytometry (FC) instruments settings classically rely on local establishment of photomultipliers (PMT) voltages adapted to the measurements expected to be performed. In the era of multiparameter FC (MFC), it appears more and more desirable that comparable patterns of fluorescence are obtained in different settings. This relies on a harmonization of settings between instruments. Although this has been shown to be feasible within a given brand of flow cytometers, little information is available about broader comparisons in a given center or in a multicenter fashion. Here, we report a two-phase series of experiments first performed between a Canto II (BD Biosciences) and a Navios (Beckman Coulter) instruments in the same center. PMT values adjusted on the reference instrument (RI) Canto II were used to establish target values for PMT settings on the paired Navios practice instrument (PI). This allowed to show the good correlation of all but peaks 1 and 2 of Rainbow(®) beads between RI and PI. Using 4- or 8-color stained leukocytes, the similitude of the settings was further confirmed. A complex set of matrices was then established between five centers all equipped with both instruments. Using Bland & Altman difference comparisons for median fluorescence values, it was shown that using either Rainbow beads or CD16 stained polymorphonuclears to set-up target values on the RI CantoII, highly superimposable results could be obtained on all 9 PI. The latter were obtained using Rainbow beads or Compbeads(®) for comparisons. In summary, this two-phase study demonstrates the feasibility of different methods allowing for a robust harmonization of settings for MFC., (© 2013 International Society for Advancement of Cytometry.)
- Published
- 2013
- Full Text
- View/download PDF
141. Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases.
- Author
-
Traverse-Glehen A, Bachy E, Baseggio L, Callet-Bauchu E, Gazzo S, Verney A, Hayette S, Jallades L, Ffrench M, Salles G, Coiffier B, Felman P, and Berger F
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Lymphoma, B-Cell, Marginal Zone pathology, Male, Middle Aged, Myeloid Differentiation Factor 88 genetics, Prognosis, Splenic Neoplasms pathology, Chromosome Aberrations, Genes, Immunoglobulin Heavy Chain, Lymphoma, B-Cell, Marginal Zone genetics, Lymphoma, B-Cell, Marginal Zone immunology, Mutation, Splenic Neoplasms genetics, Splenic Neoplasms immunology
- Abstract
Aims: To describe 76 cases of splenic marginal zone lymphoma (SMZL), including correlations with clinical and other characteristics., Methods and Results: Patients were predominantly female, with a median age of 62 years. The main clinical presentation was splenomegaly, except for eight cases presenting with evolution of autoimmune disorders or spontaneous splenic rupture. White pulp infiltration was nodular, with a monophasic (42%) or biphasic (53%) pattern, and associated diffuse or nodular infiltration of the red pulp, except for four cases which had atrophic white pulp. Plasmacytic differentiation and the MYD88 L265P mutation were observed in 18% and 5% of the cases, respectively. Histological progression was considered in cases with a significant association of large cells with Ki67 > 30% and macronodular architecture (P = 0.001). Other significant correlations were found between del7q (44%) and del6q (17%) (P = 0.018), IGHV1-2*04 segment usage (35%) (P = 0.001) and unmutated IGHV (39%) (P = 0.019), and between CD5 expression (27%) and higher lymphocytosis (P = 0.002). Patients requiring intensive chemotherapy after splenectomy because of clinical and/or histological progression had significantly shorter overall survival (P = 0.012)., Conclusions: We report the histological spectrum of SMZL, and discuss the differential diagnosis and requirement for molecular and cytogenetic analysis in atypical cases., (© 2013 Blackwell Publishing Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
142. In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia.
- Author
-
Baseggio L, Geay MO, Gazzo S, Berger F, Traverse-Glehen A, Ffrench M, Hayette S, Callet-Bauchu E, Verney A, Morel D, Jallades L, Magaud JP, Salles G, and Felman P
- Subjects
- Chromosomes, Human, Pair 12 genetics, Chromosomes, Human, Pair 14 genetics, Chromosomes, Human, Pair 18 genetics, Humans, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Lymphocytosis genetics, Lymphocytosis pathology, Lymphocytosis therapy, Lymphoproliferative Disorders pathology, Lymphoproliferative Disorders therapy, Male, Middle Aged, Translocation, Genetic, Treatment Outcome, Trisomy, Genes, bcl-2 genetics, Immunoglobulin Heavy Chains genetics, Lymphoproliferative Disorders genetics, Oncogene Fusion
- Abstract
The translocation t(14;18) and its t(2;18) and t(18,22) variants, which involve the BCL2 genetic hallmark for follicular lymphoma (FL), have been reported in several cases of chronic B-cell lymphoproliferative disease (CLPD) and frequently in chronic lymphocytic leukaemia (CLL). We describe here the clinical, morphological, immunological, cytogenetic and molecular findings from 37 cases of t(14;18)-positive CLPD, identified from our series of non-FL B-cell neoplasms (n=993) that were routinely analysed in peripheral blood by conventional cytogenetics analyses. The FL diagnosis was excluded by morphology and immunology (the samples were CD10 negative in all cases). The BCL2 translocations were observed in 22 CLL cases, including 7 monoclonal B-cell lymphocytosis (MBL) cases re-classified according to the new International Workshop on CLL criteria, six small lymphocytic lymphoma (SLL) cases, 1 splenic marginal zone lymphoma (SMZL) case and eight cases of unclassifiable CLPD with overlapping CLL/MZL features. In the CLL cases, the IGH/BCL2 fusion was remarkably associated with trisomy 12 (13/22) and mutated IGHV status (20/21) and did not affect the outcome. Moreover, most of these CLLs harboured a low mutation load of BCL6 gene and unmutated FAS (CD95) loci, which points to a post-germinal-centre cellular origin., (© 2012 Blackwell Publishing Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
143. Unusual spheroids in cerebrospinal fluid.
- Author
-
Jallades L, Jourdy Y, Morel D, Goedert G, Baseggio L, and Felman P
- Subjects
- Adult, Humans, Lymphoma, AIDS-Related cerebrospinal fluid, Male, Plasmacytoma cerebrospinal fluid, Cerebrospinal Fluid chemistry, Lymphoma, AIDS-Related diagnosis, Plasmacytoma diagnosis
- Published
- 2012
- Full Text
- View/download PDF
144. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity.
- Author
-
Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Felman P, and Berger F
- Subjects
- Animals, Humans, Leukemia, Hairy Cell genetics, Mutation, Proto-Oncogene Proteins B-raf genetics, Lymphoma, B-Cell genetics, Splenic Neoplasms genetics
- Abstract
Among splenic lymphomas with circulating cells presenting cytoplasmic projections, a homogeneous clinico-pathological entity has been recently individualized as Splenic Diffuse Red Pulp Lymphomas (SDRPL) and introduced in the provisional "unclassifiable splenic lymphoma" category of the current updated WHO classification until more is known. SDRPL presents characteristic circulating basophilic villous lymphocytes and diffuse infiltration of the splenic red pulp, distinct from Splenic Marginal Zone Lymphoma (SMZL) and Hairy Cell Leukemia (HCL), but reminiscent of HCL-Variant (HCL-V). Series of SDRPL remain sparse in the literature and controversies exist about the relationship with other splenic lymphomas. Distinction of these disorders at diagnosis can be difficult, but an adequate diagnosis is important due to differences in patient management and clinical outcome. Especially, BRAF mutations have been detected in almost all patients with HCL that may have implications for pathogenesis, diagnosis, and targeted therapy. This review will report literature data and discuss the differential diagnosis, particularly with HCL-V.
- Published
- 2012
145. CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma.
- Author
-
Baseggio L, Traverse-Glehen A, Berger F, Ffrench M, Jallades L, Morel D, Goedert G, Magaud JP, Salles G, and Felman P
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, CD analysis, Antigens, CD biosynthesis, Antigens, Differentiation, T-Lymphocyte analysis, Apoptosis Regulatory Proteins analysis, Apoptosis Regulatory Proteins biosynthesis, Biomarkers, Tumor analysis, Biomarkers, Tumor blood, Cell Separation, Female, Flow Cytometry, Humans, Inducible T-Cell Co-Stimulator Protein, Lymph Nodes metabolism, Lymph Nodes pathology, Lymphoma, T-Cell pathology, Male, Middle Aged, Neprilysin analysis, Programmed Cell Death 1 Receptor, Antigens, Differentiation, T-Lymphocyte biosynthesis, Immunoblastic Lymphadenopathy metabolism, Lymphoma, T-Cell metabolism, Neoplastic Cells, Circulating metabolism, Neprilysin biosynthesis
- Abstract
Angioimmunoblastic T-cell lymphoma is immunologically defined by the expression of CD10 and the follicular helper T cell (T(FH)) markers such as CXCL13, programmed death-1 (PD-1) and inducible T-cell costimulator (ICOS). This T(FH) profile has been mainly reported by immunohistochemistry. Here, using multiparametric flow cytometry, the relevance of ICOS and PD-1 to angioimmunoblastic T-cell lymphoma diagnosis was evaluated in lymph node (n=15) as well as in peripheral blood (n=13) among a series of 28 angioimmunoblastic T-cell lymphoma cases, in addition to the CD10 expression (available in 26 lymph node and 15 peripheral blood specimens). In this series, CD10 expression was present in 23/26 (88%) lymph node and in 12/15 (80%) peripheral blood cases and ICOS in 13/15 (87%) lymph node and in 6/13 (47%) peripheral blood cases, whereas neither significant CD10 nor ICOS T cells were identified in the control group (lymph nodes with reactive hyperplasia=10, peripheral blood of healthy donors=15). PD-1 expression was less informative as observed in both angioimmunoblastic T-cell lymphoma and control cases. The multiparametric approach allowed us to confirm the frequent blood dissemination in angioimmunoblastic T-cell lymphoma and to show that circulating neoplastic T cells correspond more often to a CD10-positive subset than to an ICOS-positive subset. Consequently, if ICOS constitutes an additional feature for the diagnosis of angioimmunoblastic T-cell lymphoma, it appears less sensitive than CD10 expression for the detection of circulating neoplastic T cells.
- Published
- 2011
- Full Text
- View/download PDF
146. Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometry.
- Author
-
Rolland D, Bouamrani A, Houlgatte R, Barbarat A, Ramus C, Arlotto M, Ballester B, Berger F, Felman P, Callet-Bauchu E, Baseggio L, Traverse-Glehen A, Brugière S, Garin J, Coiffier B, Berger F, and Thieblemont C
- Subjects
- Biomarkers, Tumor, Computational Biology, Histones metabolism, Humans, Protein Array Analysis, Signal Recognition Particle metabolism, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Lymphoma, B-Cell, Marginal Zone metabolism, Lymphoma, B-Cell, Marginal Zone pathology, Lymphoma, Mantle-Cell metabolism, Lymphoma, Mantle-Cell pathology, Proteomics, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- Abstract
Mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL) are small B-cell non-Hodgkin lymphomas (NHLs) that may be difficult to distinguish. In order to identify specific proteomic biomarkers, differential proteomic analysis of these three NHLs was performed using surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS). Whole cell lysates obtained from 18 MCL, 20 SLL, and 20 MZL biopsies were applied on two different ProteinChips (cationic and anionic). Hierarchical clustering and discriminating scores combined with an innovative bio-informatics microdissection strategy allowed us to distinguish specific lymphoma proteomic signatures based on the expression of 37 protein peaks. SELDI-assisted protein purification combined with nano-liquid chromatography (LC) quadrupole-time of flight tandem mass spectrometry (Q-TOF MS/MS) was used to identify proteins overexpressed in both MCL and SLL tumors. Among them two histones, H2B and H4, were identified in MCL tumor biopsies and the signal recognition particle 9 kDa protein, SRP9, in SLL tumor biopsies.
- Published
- 2011
- Full Text
- View/download PDF
147. Simultaneous detection of clonal expansion of large granular lymphocytes and breast cancer in blood.
- Author
-
Baseggio L, Regad AL, Ffrench M, and Felman P
- Subjects
- Blood Cells pathology, Cell Proliferation, Clone Cells pathology, Female, Humans, Middle Aged, Breast Neoplasms pathology, Lymphocytes pathology, Neoplastic Cells, Circulating pathology
- Published
- 2010
- Full Text
- View/download PDF
148. Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity?
- Author
-
Traverse-Glehen A, Baseggio L, Callet-Bauchu E, Ffrench M, Coiffier B, Salles G, Felman P, and Berger F
- Subjects
- Aged, Female, Humans, Immunoglobulin Heavy Chains genetics, Male, Middle Aged, Leukemia, Hairy Cell classification, Lymphoma, B-Cell, Marginal Zone classification, Splenic Neoplasms classification
- Published
- 2010
- Full Text
- View/download PDF
149. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
- Author
-
Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M, Couris CM, Thieblemont C, Morel D, Coiffier B, Salles G, and Felman P
- Subjects
- Adult, Aged, Aged, 80 and over, Chromosomes, Human, Pair 11 genetics, Chromosomes, Human, Pair 14 genetics, Cytogenetic Analysis, Female, Flow Cytometry, Follow-Up Studies, Humans, Immunoenzyme Techniques, Immunoglobulin Heavy Chains genetics, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Lymphoma, B-Cell, Marginal Zone genetics, Lymphoma, Mantle-Cell diagnosis, Lymphoma, Mantle-Cell genetics, Lymphoma, Mantle-Cell metabolism, Male, Middle Aged, Prognosis, Splenic Neoplasms genetics, Translocation, Genetic, Waldenstrom Macroglobulinemia diagnosis, Waldenstrom Macroglobulinemia genetics, Waldenstrom Macroglobulinemia metabolism, CD5 Antigens metabolism, Lymphocytosis pathology, Lymphoma, B-Cell, Marginal Zone diagnosis, Lymphoma, B-Cell, Marginal Zone metabolism, Splenic Neoplasms diagnosis, Splenic Neoplasms metabolism
- Abstract
Background: Classically, splenic marginal zone B-cell lymphoma is characterized by the absence of CD5 expression. Cases of apparent splenic marginal zone B-cell lymphoma showing CD5 expression, as diagnosed by blood studies, have been described; however, in the absence of histological evidence, the correct diagnosis of these cases is controversial because of possible confusion with other CD5-positive small B-cell neoplasms., Design and Methods: We report a series of 24 CD5-positive, t(11;14)-negative cases of splenic marginal zone B-cell lymphoma diagnosed by flow cytometry studies of blood and histologically proven on spleen sections. Clinical data as well as morphological, immunological, cytogenetic and molecular characteristics were assessed to evaluate the similarities and differences of these cases with those of classical CD5-negative splenic marginal zone B-cell lymphoma., Results: The CD5 expression detected in blood by flow cytometry was confirmed in most cases by immunohistochemistry on spleen sections. In general, cases of CD5-positive and CD5-negative splenic marginal zone B-cell lymphoma did not appear different and, in particular, they showed similar karyotypic changes such as 7q deletion, trisomy 3, trisomy 18 and biased IGHV usage (i.e. VH1-2). The main differences were a higher lymphocyte count at diagnosis (8.15x10(9)/L versus 3.90x10(9)/L; P=0.005) and more frequent diffuse bone marrow infiltration (34% versus 8%; P=0.03) in the CD5-positive group. A tendency to a more mutated IGHV status in the CD5 positive cases was observed (80% versus 54.5%; (P=0.11). No significant differences in outcome were found in relation to CD5 expression., Conclusions: This study confirms the existence of cases of CD5-positive splenic marginal zone B-cell lymphoma and shows that these cases are closely related to classical splenic marginal zone lymphoma. Whether or not CD5-positive splenic marginal zone B-cell lymphoma constitutes a true subset obviously requires the study of more cases.
- Published
- 2010
- Full Text
- View/download PDF
150. Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells.
- Author
-
Chebel A, Rouault JP, Urbanowicz I, Baseggio L, Chien WW, Salles G, and Ffrench M
- Subjects
- Gene Expression Regulation, Enzymologic drug effects, HeLa Cells, Humans, Immunosuppressive Agents pharmacology, Jurkat Cells, Lymphocyte Activation drug effects, Lymphocyte Activation physiology, Mutation, NFATC Transcription Factors genetics, RNA, Messenger biosynthesis, RNA, Messenger genetics, Telomerase genetics, Transcription, Genetic drug effects, Gene Expression Regulation, Enzymologic physiology, NFATC Transcription Factors metabolism, Response Elements physiology, Telomerase biosynthesis, Transcription, Genetic physiology
- Abstract
Telomerase is essential for telomere maintenance, and its activation is thought to be a critical step in cellular immortalization and tumorigenesis. Human telomerase reverse transcriptase (hTERT) is a major component of telomerase activity. We show here that hTERT is expressed soon after lymphocyte activation and that its expression is inhibited by rapamycin, wortmannin, and FK506, which was the most potent inhibitor. These results suggest a potential role for the transcription factor nuclear factor of activated T cells (NFAT) in the regulation of hTERT expression. Five putative NFAT-binding sites were identified in the hTERT promoter. In luciferase assays, the hTERT promoter was activated by overexpressed NFAT1. Moreover, serial deletions revealed that the promoter activation was mainly due to a -40 NFAT1-binding site flanked by two SP1-binding sites. Mutation of the -40 NFAT-binding site caused a 53% reduction in the transcriptional activity of hTERT promoter. Simultaneous mutations of the -40 NFAT-responsive element together with one or both SP1-binding sites led to a more dramatic decrease in luciferase activity than single mutations, suggesting a functional synergy between NFAT1 and SP1 in hTERT transcriptional regulation. NFAT1 overexpression in MCF7 and Jurkat cell lines induced an increase in endogenous hTERT mRNA expression. Inversely, its down-regulation was induced by NFAT1 silencing. Furthermore, chromatin immunoprecipitation assay demonstrated that NFAT1 directly binds to two sites (-40 and -775) in the endogenous hTERT promoter. Thus, we show for the first time the direct involvement of NFAT1 in the transcriptional regulation of hTERT.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.